All articles tagged with #neurovascular
A MUSC study suggests EPA from fish oil may hinder brain repair and vascular stability after repeated mild traumatic brain injuries, with DHA showing different effects, highlighting context-dependent omega-3 impacts and the need for precision nutrition research.
A MUSC study published in Cell Reports shows that EPA, an omega-3 fatty acid in fish oil, can hinder brain repair after repetitive mild traumatic brain injuries, while DHA remains generally beneficial; in mice and human endothelial cells EPA reduced repair and angiogenesis, with postmortem CTE tissue showing related lipid and vascular changes. The authors caution that omega-3 effects are context-dependent and not universally protective, urging more research into precision nutrition and EPA handling in the brain.
A Nature Communications study reveals brown fat uses SLIT3 fragments, produced by BMP1, to drive blood vessel and nerve growth essential for thermogenesis. In mice, removing SLIT3 or its receptor PLXNA1 impairs nerve and vascular networks and lowers heat production, while human fat analyses suggest SLIT3 activity may influence obesity and insulin sensitivity, pointing to therapies that increase energy expenditure rather than curb appetite.
Boston Scientific announced a definitive agreement to acquire Penumbra in a cash-and-stock deal valued at about $14.5 billion (Penumbra at $374/share), creating a scaled entry into mechanical thrombectomy and neurovascular therapies. The transaction finances roughly 73% cash and 27% Boston Scientific stock (about $11 billion cash financed with cash on hand and new debt) and is expected to close in 2026 pending stockholder and regulatory approvals. Penumbra reported about $1.4 billion in revenue for 2025. Penumbra stockholders may elect cash or Boston Scientific shares; Adam Elsesser plans to take Boston Scientific stock for all his Penumbra shares. The deal is dilutive to GAAP earnings in the near term and to adjusted EPS in the near term, with accretion expected in later years.
Boston Scientific announced a cash-and-stock deal to acquire Penumbra for about $14.5 billion (Penumbra at $374 per share), expanding its cardiovascular portfolio with Penumbra’s mechanical thrombectomy and neurovascular tech. The transaction is ~73% cash and ~27% stock, financed with cash on hand and new debt, and is expected to close in 2026 after shareholder and regulatory approvals. Penumbra’s 2025 revenue is about $1.4 billion; the deal aims to broaden access to vascular therapies and drive long-term growth, though GAAP earnings are expected to be dilutive in the near term.
Scientists at the University of Vermont have discovered that increasing levels of the phospholipid PIP2 in brain cell membranes may help regulate blood flow in the brain by inhibiting the Piezo1 protein, potentially offering a new approach to treat dementia and related neurovascular diseases.
Scientists at the University of Vermont have discovered that restoring levels of the phospholipid PIP2 can reduce overactivity of the Piezo1 protein in brain blood vessels, potentially improving blood flow and alleviating symptoms of dementia, offering a promising new avenue for treatment.